Clinical Trial Update: Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

View source ↗

Summary

This completed postmarketing prospective study evaluated the risk of herpetic infection in melanoma patients treated with IMLYGIC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpetic Infection
• Melanoma

Drugs mentioned

• Imlygic (Talimogene laherparepvec)

Snippet

Sponsor: Amgen | Conditions: Melanoma, Herpetic Infection | Status: COMPLETED